BXCL501 for Agitation in Schizophrenia (DEX)
Safety and Efficacy of BXCL501, a Sublingual Film Delivery of Dexmedetomidine for the Treatment of Acute Agitation in Schizophrenia
Sponsor: Yale University
This PHASE1 trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Yale University leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
13 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed · Phase: PHASE2 → PHASE1
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Feb 2021 — Feb 2022 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2018 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .